Talphera Inc. (TLPH)

[$$$eeker]

Equities research analysts at Roth Capital cut their price objective on shares of AcelRx Pharmaceuticals (NASDAQ:ACRX) to $16.00 in a research note issued to investors on Monday. The firm currently has a “buy” rating on the stock. Roth Capital’s target price indicates a potential upside of 47.74% from the stock’s previous close.
A number of other analysts have also recently weighed in on ACRX. Analysts at Canaccord Genuity cut their price target on shares of AcelRx Pharmaceuticals from $16.00 to $8.00 in a research note on Monday. They now have a “hold” rating on the stock. Analysts at JMP Securities initiated coverage on shares of AcelRx Pharmaceuticals in a research note on Tuesday, June 17th. They set an “outperform” rating and a $14.00 price target on the stock. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $15.21.
Shares of AcelRx Pharmaceuticals (NASDAQ:ACRX) opened at 10.83 on Monday. AcelRx Pharmaceuticals has a 52 week low of $6.04 and a 52 week high of $13.64. The stock has a 50-day moving average of $10.15 and a 200-day moving average of $10.84. The company’s market cap is $469.1 million.
AcelRx Pharmaceuticals (NASDAQ:ACRX) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.22) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.23) by $0.01. Analysts expect that AcelRx Pharmaceuticals will post $-1.05 EPS for the current fiscal year.

http://bit.ly/1rRsOsO